Carl Cook

470 citations

12 papers · 137 · h-index 8

Impact in

Oncology
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
Otorhinolaryngology

Papers in

Oncology 8
- HER2/EGFR in Cancer Research 2
- Lung Cancer Research Studies 2
- Cancer Immunotherapy and Biomarkers 2
- Peptidase Inhibition and Analysis 1
Pulmonary and Respiratory Medicine 7
- Lung Cancer Treatments and Mutations 6
- Advanced Breast Cancer Therapies 3

Co-authors: Ganesh Mugundu (7 shared papers)Martin Scott (4 shared papers)David S. Hong (4 shared papers)Ezra E.W. Cohen (2 shared papers)Minal Mehta (3 shared papers)Patricia McCoon (3 shared papers)Ulrich Keilholz (2 shared papers)Pat Mitchell (2 shared papers)
Journals: Journal of Clinical Oncology (5 papers)Annals of Oncology (3 papers)Molecular Cancer Therapeutics (1 paper)Journal of Pharmacokinetics and Pharmacodynamics (1 paper)Cancer Research (1 paper)
Partner nations: United States United Kingdom Spain

In The Last Decade

Carl Cook

11 papers receiving 136 citations

Peers

Countries citing papers authored by Carl Cook

Since Specialization

Citations

This map shows the geographic impact of Carl Cook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Cook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Cook more than expected).

Fields of papers citing papers by Carl Cook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl Cook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Cook. The network helps show where Carl Cook may publish in the future.

Co-authors

The 25 scholars most cited alongside Carl Cook, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Carl Cook Line = papers co-authored together Carl Cook links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work
1	A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results Annals of Oncology ·Ezra E.W. Cohen, Kevin J. Harrington, David S. Hong, Ricard Mesı́a, Irene Braña, Pedro Pérez Segura, Trisha M. Wise‐Draper, Martin Scott, Pat Mitchell, Ganesh Mugundu, Patricia McCoon, Carl Cook, Minal Mehta, Ulrich Keilholz	2018	30
2	Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN) Annals of Oncology ·Ezra E.W. Cohen, David S. Hong, T. Wise Draper, William N. William, D. Schrijvers, R. Mesía Nin, Martin Scott, Paul D. Lyne, Ganesh Mugundu, Patricia McCoon, Carl Cook, Minal Mehta, Ulrich Keilholz	2017	19
3	First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data. Journal of Clinical Oncology ·Judy Sing-Zan Wang, Serena De Vita, Janet L. Karlix, Carl Cook, Gillian M. Littlewood, Maureen M. Hattersley, Ganesh Moorthy, Helena Edlund, Giulia Fabbri, Kris F. Sachsenmeier, Chris Davison, Edwin Clark, Kathleen N. Moore, Todd M. Bauer, Susanna V. Ulahannan, Manish R. Patel, Erika Hamilton	2019	17
4	Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies. Journal of Clinical Oncology ·Alison M. Schram, Jordi Rodón, Manish R. Patel, Shekeab Jauhari, Jasgit C. Sachdev, Viola W. Zhu, Patricia LoRusso, Danny Nguyen, Xiuning Le, Matthew O’Connor, Nigel J. Waters, Carl Cook, Karsten Witt, Rachel Humphrey, Pasi A. Jänne, Erika Hamilton	2021	16
5	Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch Journal of Pharmacokinetics and Pharmacodynamics ·Hongmei Xu, Xiao Tong, Ganesh Mugundu, Martin Scott, Carl Cook, Cecilia Arfvidsson, Elizabeth J. Pease, Diansong Zhou, Paul D. Lyne, Nidal Al‐Huniti	2019	11
6	A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors. Journal of Clinical Oncology ·Erika Hamilton, Judy Sing-Zan Wang, Gerald S. Falchook, Suzanne F. Jones, Carl Cook, Ganesh Mugundu, Philip J. Jewsbury, Mark J. O’Connor, Andrew J. Pierce, Bob T. Li, Amit M. Oza, Jeffrey R. Infante, Howard A. Burris, David R. Spigel	2016	10
7	A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts. Journal of Clinical Oncology ·Todd M. Bauer, Suzanne F. Jones, Carol Greenlees, Carl Cook, Philip J. Jewsbury, Ganesh Mugundu, Tim French, Andrew J. Pierce, Mark J. O’Connor, Naomi Laing, J. Carl Barrett, Dawn Michelle Stults, Melissa L. Johnson, J. Thaddeus Beck, Kathleen N. Moore, Jeffrey R. Infante, Howard A. Burris, David R. Spigel	2016	8
8	A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN Annals of Oncology ·David S. Hong, Gerald S. Falchook, Carl Cook, Wael A. Harb, Paul D. Lyne, Patricia McCoon, Minal Mehta, Pat Mitchell, Ganesh Mugundu, Martin Scott, J.S. Wang	2016	7
9	Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings Cancer Research ·Todd M. Bauer, Suzanne F. Jones, Carol Greenlees, Carl Cook, Ganesh Mugundu, Philip J. Jewsbury, Andrew J. Pierce, Mark J. O’Connor, Melissa L. Johnson, J. Thaddeus Beck, Kathleen N. Moore, Lowell L. Hart, J. Infante, Howard A. Burris, David R. Spigel	2016	7
10	An Artificial Neural Network for the Electrocardiographic Diagnosis of Left Ventricular Hypertrophy Critical Reviews in Biomedical Engineering ·Christie B. Hopkins, Jawal Suleman, Carl Cook	2000	6
11	Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies. Journal of Clinical Oncology ·Erika Hamilton, Manish R. Patel, Jordi Rodón, David S. Hong, Alison M. Schram, Pasi A. Jänne, Patricia LoRusso, Jasgit C. Sachdev, Sai Hong Ou, Elizabeth Buck, Matthew O’Connor, Nigel J. Waters, Karsten Witt, Carl Cook	2020	6
12	Abstract P02-04: BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastases Molecular Cancer Therapeutics ·Matthew C. Lucas, Melinda S. Merchant, Matthew O’Connor, Carl Cook, Sherri Smith, Anthony F. Trombino, Wu‐Yan Zhang, Irache Visiers, Kate Tith, Reza Foroughi, Nigel J. Waters, Iwona Wrona, Michael D. Pickard, Sudharshan Eathiraj, Karsten Witt, Christopher Roberts, Rachel Humphrey, Elizabeth Buck	2021	0

About Carl Cook

Carl Cook is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Infectious Diseases, having authored 12 papers that have together received 137 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (6 papers), Cancer Genomics and Diagnostics (3 papers), Advanced Breast Cancer Therapies (3 papers), HER2/EGFR in Cancer Research (2 papers), CRISPR and Genetic Engineering (2 papers), Lung Cancer Research Studies (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Peptidase Inhibition and Analysis (1 paper). The work is most often cited by research in Oncology (93 citations), Otorhinolaryngology (12 citations), Health Informatics (2 citations), Pulmonary and Respiratory Medicine (41 citations) and Immunology (24 citations). Carl Cook has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Ganesh Mugundu, Martin Scott, David S. Hong, Ezra E.W. Cohen, Minal Mehta, Patricia McCoon, Ulrich Keilholz, Pat Mitchell, Paul D. Lyne and Erika Hamilton. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Molecular Cancer Therapeutics, Journal of Pharmacokinetics and Pharmacodynamics and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Carl Cook

Impact in

Papers in i

In The Last Decade

Carl Cook

Peers

Countries citing papers authored by Carl Cook

Fields of papers citing papers by Carl Cook

All Works

About Carl Cook

Explore authors with similar magnitude of impact

Papers in